Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting

The 3rd European Iron Academy (EIA) took place on the 12th and 13th September 2016 in Berlin, Germany, and brought together over 450 clinicians with an interest in iron deficiency.

Iron deficiency is the most common nutritional disorder in the world and is the leading cause of anaemia. The condition occurs frequently across multiple therapeutic areas e.g. in patients with chronic diseases such as inflammatory bowel disease, heart failure and chronic kidney disease. In such conditions, inadequately managed iron deficiency has been associated with poor patient outcomes, including increased hospitalisations, reduced quality of life and even higher mortality rates.

The 3rd EIA had the goal of further raising awareness of iron deficiency and stimulating discussion amongst peers, helping them to better understand the causes, the need for improved diagnosis and the current treatment options for their patients.

The 2016 programme offered delegates the opportunity to tailor the sessions to their own clinical interests/areas of expertise; engage in interactive patient case scenarios and breakout sessions; and discuss current standards in iron deficiency management with experts in Q&A-style sessions.

The 3rd EIA is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide participants with CME credits, and is supported by an educational grant from Vifor Pharma.

“We are delighted to be running the 3rd EIA this year, which specifically addresses the need for continuing medical education on iron deficiency,” said Professor Stefan Anker (Germany), EIA 2016 co-Chair and Professor of Innovative Clinical Trials (Cardiology & Cachexia Research) at the University Medical Center Göttingen, Germany.

“This year’s programme will review the latest data relating to the diagnosis and treatment of iron deficiency within a number of key therapy areas, including cardiology, gastroenterology, nephrology and haematology, and showcases the EIA’s all-encompassing approach to education and improving patient outcomes in many disease areas.”

Source:

European Iron Academy (EIA)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    CSL Ltd. (2022, December 19). Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting. News-Medical. Retrieved on December 23, 2024 from https://www.news-medical.net/news/20160916/Leading-experts-in-iron-deficiency-to-participate-in-3rd-European-Iron-Academy-meeting.aspx.

  • MLA

    CSL Ltd. "Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting". News-Medical. 23 December 2024. <https://www.news-medical.net/news/20160916/Leading-experts-in-iron-deficiency-to-participate-in-3rd-European-Iron-Academy-meeting.aspx>.

  • Chicago

    CSL Ltd. "Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting". News-Medical. https://www.news-medical.net/news/20160916/Leading-experts-in-iron-deficiency-to-participate-in-3rd-European-Iron-Academy-meeting.aspx. (accessed December 23, 2024).

  • Harvard

    CSL Ltd. 2022. Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting. News-Medical, viewed 23 December 2024, https://www.news-medical.net/news/20160916/Leading-experts-in-iron-deficiency-to-participate-in-3rd-European-Iron-Academy-meeting.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development